Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Free Report) – Analysts at HC Wainwright reduced their FY2024 earnings per share estimates for shares of Kiora Pharmaceuticals in a report released on Monday, November 11th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $1.28 per share for the year, down from their previous estimate of $1.58. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Kiora Pharmaceuticals’ current full-year earnings is $0.89 per share. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at $0.67 EPS and FY2025 earnings at ($2.76) EPS.
Kiora Pharmaceuticals Trading Down 3.1 %
KPRX opened at $3.29 on Thursday. The company’s 50-day moving average price is $3.52 and its 200 day moving average price is $4.27. Kiora Pharmaceuticals has a fifty-two week low of $3.00 and a fifty-two week high of $8.98.
Institutional Trading of Kiora Pharmaceuticals
An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC acquired a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals comprises 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 16th biggest position. Stonepine Capital Management LLC owned about 6.86% of Kiora Pharmaceuticals at the end of the most recent quarter. 76.97% of the stock is currently owned by hedge funds and other institutional investors.
Kiora Pharmaceuticals Company Profile
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Further Reading
- Five stocks we like better than Kiora Pharmaceuticals
- 3 Warren Buffett Stocks to Buy Now
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Which Wall Street Analysts are the Most Accurate?
- Top-Performing Non-Leveraged ETFs This Year
- Investing in Commodities: What Are They? How to Invest in Them
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.